Teva Pharmaceutical Industries Limited (NYSE:TEVA) issued an update on its FY17 earnings guidance on Monday morning. The company provided earnings per share guidance of $4.90-5.30 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.89. The company issued revenue guidance of $23.8-24.5 billion, compared to the consensus revenue estimate of $23.77 billion.
Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) opened at 32.19 on Monday. Teva Pharmaceutical Industries Limited has a 1-year low of $31.90 and a 1-year high of $59.35. The stock has a market cap of $32.67 billion, a P/E ratio of 18.73 and a beta of 0.58. The firm’s 50-day moving average price is $34.51 and its 200 day moving average price is $42.93.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last announced its quarterly earnings results on Monday, February 13th. The company reported $1.38 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.36 by $0.02. The business had revenue of $6.25 billion for the quarter, compared to analyst estimates of $6.26 billion. Teva Pharmaceutical Industries Limited had a return on equity of 16.75% and a net margin of 8.81%. The company’s quarterly revenue was up 33.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.32 EPS. On average, equities analysts expect that Teva Pharmaceutical Industries Limited will post $5.11 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Monday, March 20th. Stockholders of record on Thursday, March 2nd will be paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 4.22%. Teva Pharmaceutical Industries Limited’s dividend payout ratio (DPR) is 67.44%.
Several equities research analysts have recently commented on the company. Deutsche Bank AG decreased their price target on Teva Pharmaceutical Industries Limited from $68.00 to $54.00 and set a buy rating on the stock in a research note on Wednesday, November 16th. Morgan Stanley lowered Teva Pharmaceutical Industries Limited from an overweight rating to an equal weight rating and decreased their price target for the stock from $63.00 to $42.00 in a research note on Sunday, December 4th. Jefferies Group LLC reissued a hold rating and set a $36.00 price target on shares of Teva Pharmaceutical Industries Limited in a research note on Monday, January 9th. Royal Bank Of Canada decreased their price target on Teva Pharmaceutical Industries Limited from $71.00 to $58.00 and set an outperform rating on the stock in a research note on Monday, November 14th. Finally, BTIG Research lowered Teva Pharmaceutical Industries Limited from a buy rating to a neutral rating in a research note on Sunday, December 4th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company. Teva Pharmaceutical Industries Limited presently has an average rating of Buy and a consensus target price of $53.88.
Teva Pharmaceutical Industries Limited Company Profile
Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/teva-pharmaceutical-industries-limited-teva-releases-fy17-earnings-guidance/1658065.html
Receive News & Ratings for Teva Pharmaceutical Industries Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Limited and related companies with MarketBeat.com's FREE daily email newsletter.